Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06070103
Other study ID # D,A,S among diabetic Patients
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date April 1, 2024
Est. completion date December 31, 2024

Study information

Verified date February 2024
Source Assiut University
Contact Alaa ab mohamed, master
Phone 01142876510
Email dr.alaa2199@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

1. Assessment the prevalence of psychiatric disorders in diabetic patient in Assuit University Hospital. 2. Determine the associated factors with the psychiatric disorders.


Description:

Across the world, both Diabetes and Psychiatric disorders are on rise. Diabetes strongly affects disability, mortality, and global health expenditure. Diabetes mellitus is a disabling long-term health condition that is common and growing. Globally, it affects 10.5% of the population and is the leading cause of lost disability-adjusted life years Type 1 diabetes is a lifelong autoimmune disease characterized by insulin deficiency and resultant hyperglycemia. It constitutes around 10% of all diagnosed cases of diabetes and its incidence is increasing globally. Type 2 diabetes mellitus (DM2) is a chronic metabolic disease characterized by an increase in normal serum glucose levels (hyperglycemia). Psychological disorders can occur in people with diabetes of all ages. Type 1 diabetes seems to have a higher prevalence of psychological disorders than type 2 diabetes. About 15%-20% of people with diabetes are suffering from depression. the exact cause of depression in people with diabetes is unknown, it is likely complex due to a combination of genetic, physiological, and psychological factors. Depression and anxiety could worsen the prognosis of diabetes by reducing the patients' ability to self-care and increasing non-compliance to treatments while increasing the risk of serious short-term and long-term complications such as blindness, amputations, stroke, and even premature death.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 325
Est. completion date December 31, 2024
Est. primary completion date November 30, 2024
Accepts healthy volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: Age between 18 and 70 years Diagnosed according to criteria of the American Diabetes Association fasting plasma glucose (FPG) level of 126 mg/dL (7.0 mmol/L) or higher or A 2-hour plasma glucose level of 200 mg/dL (11.1 mmol/L) or higher during a 75-g oral glucose tolerance test (OGTT). Exclusion Criteria: - Patient with cognitive difficulties - To be very sick and unable to give consent - Women who were pregnant or had given birth in the last 6 months

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Outcome

Type Measure Description Time frame Safety issue
Primary Depression ,Anxiety and stress disorders among diabetic patients in Assuit University Hospitals. Assessment the prevalence of psychiatric disorders in diabetic patient in Assuit University Hospital.
Determine the associated factors with the psychiatric disorders.
Baseline
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A